oncology
Trump Picks National Cancer Institute Director
Trump Picks National Cancer Institute Director
Kerry Grens | Jun 12, 2017
Ned Sharpless currently leads the cancer center at the University of North Carolina, Chapel Hill.
Rare T Cells Fight Cancer
Rare T Cells Fight Cancer
Jef Akst | May 1, 2017
A new approach to immunotherapy finds that the immune-cell clonotypes that come to the rescue start out at very low frequencies.
A History of Screening for Natural Products to Fight Cancer
A History of Screening for Natural Products to Fight Cancer
Jef Akst | Apr 1, 2017
In the middle of the 20th century, the National Cancer Institute began testing plant extracts for chemotherapeutic potential—helping to discover some drugs still in use today.
How Cancers Evolve Drug Resistance
How Cancers Evolve Drug Resistance
Anna Azvolinsky | Apr 1, 2017
Researchers unravel the sophisticated ways cancers evade treatments, including immunotherapies, designed to destroy them.
Infographic: Targeting Cancer Antigens
Infographic: Targeting Cancer Antigens
Stephen P. Schoenberger and Ezra Cohen | Mar 31, 2017
Neoantigens may serve as valuable targets for new immunotherapies.
Infographic: Mechanisms of Resistance
Infographic: Mechanisms of Resistance
Anna Azvolinsky | Mar 31, 2017
Cancers appear to be able to evolve resistance to many of the therapies doctors have tried.
Newly Found White Blood Cell Withstands Chemotherapy
Newly Found White Blood Cell Withstands Chemotherapy
Ben Andrew Henry | Jan 1, 2017
Vaccine-induced macrophages open a new realm of study into remodeling the immune system to reduce the risk of infections during cancer treatment.
Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy
Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy
David Harris | Dec 15, 2016
New approaches to treating cancer have shown great promise, but they also come with serious risks that give us cause for concern.
Pfizer to Buy Medivation for $14 Billion
Pfizer to Buy Medivation for $14 Billion
Bob Grant | Aug 22, 2016
The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.
Renowned Cancer Theorist Dies
Renowned Cancer Theorist Dies
Alison F. Takemura | Jul 12, 2016
Alfred Knudson, who formulated the “two-hit” theory on the origins of cancer, has passed away at age 93.